Basic Info.Model NO.910463-68-2CAS No.910463-68-2Transport PackageBagSpecification1g/10g/100gTrademarkINNOOriginChinaProduction Capacity100kg/Month
| Product Name | Sermaglutide |
| CAS No. | 910463-68-2 |
| MF | C187H291N45O59 |
| MW | 4113.57754 |
| Purity | 99.00% |
| EINECS No. | 203-405-2 |
| Grade | Pharmaceutical Grade |
| Appearance | White Powder |
| Indications | Used in the treatment of advanced prostate cancer. |
Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
